ARTICLE | Clinical News
FDA places hold on Epizyme's tazemetostat
April 23, 2018 10:43 PM UTC
Epizyme Inc. (NASDAQ:EPZM) fell $2.90 (19%) to $12.40 in after-hours trading Monday after FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma during a Phase I pediatric trial of the selective inhibitor of enhancer of zeste homolog 2 (EZH2).
The hold suspends new enrollment in U.S. clinical trials of tazemetostat. Patients already enrolled who have not experienced disease progression may continue to receive tazemetostat...
BCIQ Company Profiles
BCIQ Target Profiles